Introduction
Management strategies for fulminant hepatic failure (FHF), a rare but potentially devastating disorder defined by the presence of hepatic encephalopathy as the consequence of severe liver injury in patients without pre-existing overt liver disease, must take into account both specific treatments for the initiating drug, viral, or other cause and supportive measures to reverse components of the resultant clinical syndrome. The latter includes not only profound metabolic disturbance and coagulopathy but also hemodynamic instability, cerebral edema, renal failure, and susceptibility to infection. Accumulation of toxins such as ammonia and lactate, along with deleterious effects of vasoactive cytokines produced in response to the initiating cause of liver injury and/or complicating sepsis, contribute to the development of multiorgan dysfunction in FHF. The severity and duration of the clinical syndromes of FHF in individual patients are determined by the extent to which impairment of the liver's various metabolic and toxin-scavenging functions can be counterbalanced by liver cell regeneration, without which spontaneous recovery cannot occur.
Despite advances in supportive measures, FHF in its most severe form continues to carry a high mortality rate unless emergency orthotopic liver transplantation (OLT) is performed. Nonetheless, the rapidity of progression of the clinical syndrome along with a worldwide shortage of cadaveric donor organs result in many patients dying or developing contraindications to transplantation before a donor liver becomes available, even with priority listing. In order to help overcome this problem, living donor OLT has been introduced as a therapeutic option for FHF both in pediatric and, more recently, adult patients. Other recent interests have centred on the possibility of providing temporary liver support based on auxiliary partial organ transplantation or the use of extracorporeal devices or hepatocyte transplantation. The latter strategies act as either a "bridge" to OLT or, ideally, to allow time for or to actively promote native liver regeneration, thereby rendering OLT unnecessary.
The most likely etiology of FHF varies according to geographical location, altering the possibility of being able to apply specific therapy. Hepatotoxicity due to
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The rare but potentially devastating clinical syndrome of fulminant hepatic failure has as its components severe encephalopathy and finally cerebral edema, hemodynamic instability, renal failure, coagulopathy, profound metabolic disturbances and a particular susceptibility to bacterial and fungal infection. Despite advances in medical management, fulminant hepatic failure in its most severe form carries a high mortality rate unless urgent orthotopic liver transplantation is carried out. However, availability of cadaveric donor organs is limited and, due to the rapidly progressive clinical course in many cases, a substantial proportion of patients will die or develop contraindications to transplantation before the procedure can be performed. Consequently, recent interest has centred on living donor transplantation and the possibility of providing temporary liver support, either through auxiliary partial organ transplantation, extracorporeal perfusion or transplantation of hepatocytes, to allow time for either a liver graft to become available or native liver regeneration, on which spontaneous survival ultimately depends, to occur.
Liver Disease
acetaminophen is by far the most frequent cause of FHF in the United Kingdom, accounting for 60% to 70% of cases in recent series [1] . In keeping with a trend towards greater numbers of cases in many Western countries, acetaminophen is also the most prevalent cause of FHF in a recent series from Denmark and the United States [2, 3] . Cases of FHF after ingestion of recommended (or near recommended) doses of acetaminophen have been reported, particularly in patients with chronic exposure to enzyme-inducing drugs and alcohol. However, our experience is that the majority of instances of severe hepatotoxicity related to acetaminophen in alcoholics, as in other patients, are the direct consequence of having ingested a large dose of the drug. Most cases of hepatotoxicity occurring in relation to acetaminophen use with therapeutic rather than suicidal intent are also due to ingestion of large doses, generally over at least several days [4•]. The development of FHF due to acetaminophen may be prevented if N-acetylcysteine is given within 15 hours of exposure. Furthermore, the later use of this agent, after signs of liver necrosis have developed, has been shown in one controlled trial to ameliorate associated multi-organ failure and improve survival [5] .
Infection with hepatitis B virus (HBV) (with or without delta co-or super-infection) is the most prevalent cause of FHF in the Far East, France, and many other southern European countries where carriage rates are high. Reactivation of HBV is more prevalent than new HBV infection in some FHF series. Use of antiviral agents such as lamivudine may play a role in patients with high circulating HBV DNA levels, although viral replication is characteristically low or absent by the time of clinical presentation with FHF. Hepatitis E virus, for which no specific antiviral therapy is currently available, is the cause of up to 60% of cases of FHF in India but only 6% of cases in Western countries [6] . Similarly, hepatitis C virus (HCV) has only rarely been implicated as a cause of FHF in Europe [7, 8] , although HCV infection is found in a substantial proportion of patients with FHF in Japan and Taiwan [9, 10] . As well-recognized with HBV, instances of FHF following withdrawal of chemotherapy have been documented in patients with chronic HCV infection. Risk of FHF is increased in HCV and HIV coinfected patients treated with highly active antiretroviral therapy [11] . Irrespective of the geographical location, hepatitis A virus (HAV) is typically responsible for less than 10% of cases of FHF. The age at which HAV infection occurs influences outcome, with the risk of FHF increasing markedly in those older than 40 years. A high rate of development of FHF with a poor prognosis has been reported in patients with chronic HCV infection who acquire HAV acutely [12] , implying that those with chronic HCV infection should be vaccinated against hepatitis A.
Cryptogenic (or so called non-A to E fulminant hepatitis) cases generally constitute the second largest group both in the United States and European series. Documentation of cases of FHF due to ingestion of food contaminated with the Bacillus cereus emetic toxin [13] inhibits hepatic mitochondrial fatty-acid oxidation that raises the possibility that other mitochondrial toxins may be responsible for many cases currently considered cryptogenic in etiology. Nonacetaminophen adverse drug reactions, mostly idiosyncratic, account for approximately 10% to 15% of cases of FHF in Western countries. "Ecstasy" (3,4-methylene-dioxymethamphetamine) and other illicit drugs are increasingly recognized as causes of FHF.
Other uncommon etiologies of FHF include autoimmune hepatitis, pregnancy-related disorders such as acute fatty liver and the hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome, Amanita phalloides poisoning, veno-occlusive disease, acute Budd-Chiari syndrome, hepatic ischemia related to heart failure or septic shock, heatstroke, and Wilson's disease. Specific therapies and interventions to be considered in these latter disorders include a trial of corticosteroid therapy in autoimmune hepatitis, delivery of the fetus in pregnancy-related etiologies, use of penicillin and silibinin as antidotes in Amanita poisoning and decompressive vascular shunting (surgical or radiologically-achieved) in selected patients with veno-occlusive disease and acute Budd-Chiari syndrome. Investigation for an underlying procoagulant disorder is mandatory in this latter disorder. Interventional radiology including the placement of a transjugular intrahepatic portosystemic shunt (TIPS) and a hepatic venous angioplasty and stenting of the inferior vena cava may have a role in patients with hepatic venous outflow block, depending on the exact clinical context. Treatment of precipitating cardiac dysfunction is necessary in ischemic FHF due to left ventricular failure, along with appropriate antibiotics and vasopressor agents in septic shock. Circulatory collapse with resultant ischemic liver injury also contributes to the pathogenesis of FHF associated with heatstroke. Recognition of the rare fulminant presentation of Wilson's disease, suggested clinically by the presence of hemolysis, splenomegaly, and Kayser-Fleischer rings, is crucial as mortality in those with encephalopathy is virtually 100% without urgent OLT. By contrast, survival without transplantation can be achieved with early D-penicillamine treatment in most nonencephalopathic Wilson's disease patients who present acutely with other manifestations of severe hepatic insufficiency, highlighting the importance of early recognition of this disorder [14] .
Infection with Epstein-Barr virus, cytomegalovirus (CMV), varicella-zoster virus, adenovirus, and herpes simplex virus (HSV) must also be considered, especially in the immunosuppressed. FHF due to HSV and CMV may respond to antiviral treatment [15•]. FHF due to infection with togavirus-like particles, Papillomavirus,
